written on 20.06.2014

After three failed bids for Shire, will AbbVie try again to expand beyond Humira?


Spun off from Abbott Laboratories early last year, AbbVie right now is somewhat of a one-trick pony, with lead drug Humira–the best-selling med in the world–raking in 57% of its 2013 sales. Though it has some hot prospects in its pipeline, it could use some other revenue sources, and it apparently thinks Shire might be able to help it out in that department–and bring along some tax advantages, too.